Correlation Between BioAffinity Technologies and Catheter Precision

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BioAffinity Technologies and Catheter Precision at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioAffinity Technologies and Catheter Precision into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between bioAffinity Technologies Warrant and Catheter Precision, you can compare the effects of market volatilities on BioAffinity Technologies and Catheter Precision and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioAffinity Technologies with a short position of Catheter Precision. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioAffinity Technologies and Catheter Precision.

Diversification Opportunities for BioAffinity Technologies and Catheter Precision

0.19
  Correlation Coefficient

Average diversification

The 3 months correlation between BioAffinity and Catheter is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding bioAffinity Technologies Warra and Catheter Precision in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catheter Precision and BioAffinity Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on bioAffinity Technologies Warrant are associated (or correlated) with Catheter Precision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catheter Precision has no effect on the direction of BioAffinity Technologies i.e., BioAffinity Technologies and Catheter Precision go up and down completely randomly.

Pair Corralation between BioAffinity Technologies and Catheter Precision

Assuming the 90 days horizon bioAffinity Technologies Warrant is expected to under-perform the Catheter Precision. In addition to that, BioAffinity Technologies is 2.71 times more volatile than Catheter Precision. It trades about -0.15 of its total potential returns per unit of risk. Catheter Precision is currently generating about 0.19 per unit of volatility. If you would invest  38.00  in Catheter Precision on October 5, 2024 and sell it today you would earn a total of  7.00  from holding Catheter Precision or generate 18.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy70.0%
ValuesDaily Returns

bioAffinity Technologies Warra  vs.  Catheter Precision

 Performance 
       Timeline  
BioAffinity Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days bioAffinity Technologies Warrant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Catheter Precision 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Catheter Precision are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady basic indicators, Catheter Precision disclosed solid returns over the last few months and may actually be approaching a breakup point.

BioAffinity Technologies and Catheter Precision Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BioAffinity Technologies and Catheter Precision

The main advantage of trading using opposite BioAffinity Technologies and Catheter Precision positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioAffinity Technologies position performs unexpectedly, Catheter Precision can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catheter Precision will offset losses from the drop in Catheter Precision's long position.
The idea behind bioAffinity Technologies Warrant and Catheter Precision pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing